Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA vaccine aims to train immune system against lung cancer

NCT ID NCT05242965

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This phase II trial tests a DNA vaccine called STEMVAC in 5 people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, with the goal of activating immune cells to attack the tumor. Participants receive the vaccine along with an immune booster (GM-CSF) while on standard maintenance therapy. The study looks at safety and whether the vaccine can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
STEMVAC (a DNA vaccine targeting five cancer proteins) given with GM-CSF (an immune booster)
What this could lead to
If it works, this could point toward a new way to help the immune system recognize and attack lung cancer cells, potentially slowing tumor growth.
What could go wrong
This is a very small, early-phase trial with only 5 participants, so results may not apply broadly. The vaccine may not produce a strong enough immune response or shrink tumors, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    ACTIVE_NOT_RECRUITING

    Seattle, Washington, 98109, United States

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 98198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.